AzTrials
AzTrials

InsomniaNCT05724498

Brief Versus Standard Cognitive Behavioral Therapy for Insomnia in Veterans

A study testing Brief CBT-I and Standard CBT-I in people with Insomnia, run by VA Office of Research and Development at 2 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Insomnia is a common condition in Veterans, with prevalence rates as high as 53% among treatment-seeking Veterans. Chronic untreated insomnia is associated with increased risk for functional impairment, psychiatric illness, suicidal ideation, unhealthy lifestyles, and decreased quality of life. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Insomnia
What is being tested?
Brief CBT-I and Standard CBT-I
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
2 sitesUnited States
Study dates
1 May 2023to 1 Oct 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • A diagnosis of insomnia as classified by the (a) Diagnostic and Statistical Manual of Mental Disorders-5 (DSM 5) which includes daytime impairment in functioning for > 3 months and occurring at least 3 nights per week and (b) subjective sleep disturbance defined by an Insomnia Severity Index (ISI) score >7 at intake
  • Meets current DSM 5 criteria for a comorbid mental health disorder
  • No formal therapist guided treatment with brief or standard Cognitive-Behavioral Therapy for Insomnia within the past 2 years
  • on stable medication regimen for at least 4 weeks prior to enrollment in study.

Who cannot join

  • History of a acute or unstable neurological disorder(s), dementia, or premorbid IQ <70
  • Schizophrenia, psychotic disorder, and/or bipolar disorder
  • Suicidality more than "medium risk" as determined by the VA Comprehensive Suicide Risk Assessment
  • Sleep disturbances other than insomnia (e.g., untreated obstructive sleep apnea, periodic limb movements, narcolepsy, and/or circadian-based sleep disruptions)
  • alcohol and/or substance use disorder for 90 days prior to intake, but past history of alcohol and/or substance use is not exclusionary.

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • VA Finger Lakes Healthcare System, Canandaigua, NY

    Canandaigua, New York, 14424-1159

  • VA San Diego Healthcare System, San Diego, CA

    San Diego, California, 92161-0002

Other trials in United States

About this study

Official title: A Randomized Clinical Trial Comparing Brief and Standard Cognitive-Behavioral Therapies for Insomnia in Veterans

Insomnia is a common condition in Veterans, with prevalence rates as high as 53% among treatment-seeking Veterans. Chronic untreated insomnia is associated with increased risk for functional impairment, psychiatric illness, suicidal ideation, unhealthy lifestyles, and decreased quality of life. Cognitive-Behavioral Therapy for Insomnia (CBT-I) is recognized as the first-line treatment for insomnia. Despite its proven efficacy, CBT-I is not always readily provided and/or accessible to Veterans. To address these limitations, behavioral sleep medicine specialists have endeavored to streamline CBT-I through development of time-shortened variations of CBT-I. Although these modifications show promise for advancing care and access, studies comparing brief treatments to standard CBT-I have yet to be performed. This investigation will therefore compare a 4-session brief CBT-I to VA standard 6-session CBT-I to evaluate whether a brief intervention can provide comparable benefits to sleep, functional, and psychiatric outcomes in Veterans with insomnia.

Read the detailed description

Veterans seen in VA primary care and mental health clinics commonly present with complaints of sleep disturbance, especially insomnia. For example, in a cross-sectional study examining sleep disorders among Veterans seeking care through the Veterans Health Administration between 2000-2010, sleep apnea (47%) and insomnia (26%) were the most commonly diagnosed conditions. In a study of 375 Operation Enduring Freedom/Operation Iraqi Freedom Veterans, 45% reported extended time spent trying to fall asleep (> 30 minutes), 21% reported reduced total sleep times (< 4.5 hours), and 56% reported being awake in bed more than 15% of the night. Similarly, in another observational study of 5,552 Veterans, 57.2% of the sample population was found to have insomnia disorder. This sample also was at high-risk for a host of clinical disorders, including PTSD, TBI, and pain; all of which showed higher rates of insomnia.

Cognitive Behavioral Therapy for Insomnia (CBT-I) is a multi-component intervention that features sleep restriction, stimulus control, sleep hygiene education, cognitive therapy, and can include relaxation techniques. CBT-I is recognized as the first-line treatment for chronic insomnia and is effective in Veterans, however, limitations to use still remain. In recent years advances in treatment approaches have attempted to streamline CBT-I by focusing on delivery of specific treatment components, reducing number of treatment sessions, and/or use of technologies that provide for ease of dissemination and implementation. Brief Cognitive-Behavioral Therapy for Insomnia (bCBT-I) represents one such empirically tested brief intervention which may decrease patient burden through reduced sessions needed to achieve treatment goals and through use of hybrid treatment administration (i.e., in-person and telemedicine).

To better inform both clinical practice and future research, this investigation proposes to assess the comparative effectiveness of bCBT-I to VA standard CBT-, with several overarching goals: 1) in a randomized clinical trial (RCT), evaluate the equivalence (non-inferiority) of bCBT-I to VA standard CBT-I; 2) evaluate the impact of these treatment approaches on functional rehabilitation outcomes; 3) evaluate the impact of these treatment approaches on psychiatric symptomatology; and 4) in an exploratory fashion, determine which patient factors best predict success or failure with a given treatment as a means of developing insomnia phenotypes that might be used diagnostically to match patient characteristics and type of treatment to help optimize clinical outcomes (i.e., a "personalized medicine" approach to treatment).

The investigation timeline consists of four parts: 1) baseline assessment of sleep, functional, and psychiatric outcome measures; 2) randomization and assignment to either CBT-I or bCBT-I; 3) post-treatment assessment; and 4) 3-month follow-up assessment. Over 40 months of recruitment this study will enroll and randomize 180 Veterans on a 1:1 ratio (CBT-I:bCBT-I= 90:90) from VA primary care and mental health clinics at two Centers of Excellence sites (VA San Diego Healthcare System and Finger Lakes VAMC Healthcare System). For the primary study aim, one-sided mean difference testing will be conducted with the noninferiority margin added to the null value. Secondary analyses will utilize structural equation modeling to evaluate how CBT-I and bCBT-I influence functional and psychosocial outcomes. The Exploratory aim will utilize moderation analyses to better understand for whom either CBT-I and/or bCBT-I might be more effective.

Conditions
Insomnia
Being tested
Brief CBT-I, Standard CBT-I
Keywords
Insomnia, Cognitive-Behavioral Therapy for Insomnia, Functional Health, Mental Health, Veterans
Medical subject headings
Sleep Initiation and Maintenance Disorders, Psychological Well-Being

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Brief CBT-IBehavioural

    4 session CBT-I

  • Standard CBT-IBehavioural

    Standard VA 6 session CBT-I

Study groups in NCT05724498
Study groupRoleWhat they receive
Cognitive-Behavioral Therapy for Insomnia (CBT-I)Active comparatorCompare two behavioral interventions for insomnia
Receives: Behavioral: Brief CBT-I; Behavioral: Standard CBT-I
Standard Cognitive-Behavioral Therapy for Insomnia (CBT-I)Active comparatorStandard VA 6 session version of CBT-I
Receives: Behavioral: Brief CBT-I; Behavioral: Standard CBT-I

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Insomnia Severity Index (ISI) scores from pretreatment to follow-up

    Measure of insomnia severity (0-24; higher score equals worse insomnia)

    Measured: Week 0 (baseline) and Week 20 (follow-up)

Secondary outcomes (7)
  1. Change in Functional Outcomes of Sleep Questionnaire 10 (FOSQ-10)

    Self-report measure of the impact of sleep on daytime functioning (five domains scored 1-4; lower score equals more impairment)

    Measured: Week 0 (baseline) and Week 20 (follow-up)

  2. Change in Pittsburgh Sleep Quality Index (PSQI) scores from pretreatment to follow-up

    Self-report measure of general sleep disturbance (0-21 scale; higher score equals greater sleep disturbance)

    Measured: Week 0 (baseline) and Week 20 (follow-up)

  3. Change in WHO Disability Assessment Schedule (WHODAS 2.0)

    Self-report measure of disability and functioning (six domains scored 1-5; summary score from 0-100 with higher score equals greater disability)

    Measured: Week 0 (baseline) and Week 20 (follow-up)

  4. Change in Brief Inventory of Psychosocial Functioning (B-IPF)

    Self-report measure of PTSD related functional impairment (0-6 scale; items summed so that higher score equals greater impairment)

    Measured: Week 0 (baseline) and Week 20 (follow-up)

  5. Change in PTSD Checklist for DSM 5 (PCL-5)

    Self-report measure of symptoms in relation to a traumatic event (score 0-80; scores greater than 33 equal clinically significant level of symptoms)

    Measured: Week 0 (baseline) and Week 20 (follow-up)

  6. Change in Patient Health Questionnaire 9 (PHQ 9)

    Self-report measure of depressive symptoms (0-27 scale; higher scores equal more depressive symptoms)

    Measured: Week 0 (baseline) and Week 20 (follow-up)

  7. Change in Generalized Anxiety Disorder Scale 7 (GAD-7)

    Self-report measure of anxiety symptoms (0-21 scale; higher scores equal more anxiety symptoms)

    Measured: Week 0 (baseline) and Week 20 (follow-up)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Feb 2023
  2. Study start1 May 2023
  3. Primary completion1 Oct 2025
  4. Study completion1 Oct 2025

Why it stopped: Loss of investigator staff

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Veterans randomized to either brief (4 session) or full (6 session) Cognitive-Behavioral Therapy for Insomnia.
Masking
None (open label)
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05724498
Sponsor's protocol ID
D3840-R
Other IDs
1I01RX003840-01A2
Status last verified
Mar 2026
First submitted
2 Feb 2023
Last updated
20 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Brief CBT-I and Standard CBT-I in people with Insomnia, run by VA Office of Research and Development at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 20 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Loss of investigator staff). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Insomnia Severity Index (ISI) scores from pretreatment to follow-up (time frame: Week 0 (baseline) and Week 20 (follow-up)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in